Clinical Trial Search

Primary: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine…

Primary: Pressure Evaluation — 126; 163 mmHg

Primary: Spirometry and Specific Airway Conductance Measured by Body Plethysmography Before and After Exercise Challenge After Randomized Administration of Either Inhaled…

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 2; 3; 3 Participants

Primary: Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)…

Primary: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 — 19; 40 Participants

Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 48; 42; 46; 7 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants

Primary: Internal Jugular Venous (IJV) Cross Sectional Area — 1.2; 1.0; 1.8; 1.4 cm2

Primary: Maximum Tolerated Dose (MTD) — 4; 4 Participants

Primary: Change From Baseline in Cognitive Functioning — 10.90; 7.12 T-Scores

Primary: Number of Participants Identifying With the Three Main Themes Identified — 13 Participants

Primary: Symptomatology — 41.66; 4.34; 4.29; 4.29 score on a scale — p=0.067

Primary: Disability - WHO-DAS 2 Change — -2.81; -2.21 score on a scale — p=0.712

Primary: Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) — -2.52; -2.00 units on a scale — p=< 0.001